Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells.

Unique Identifier : AIDSLINE MED/99059495
Kinoshita S; Chen BK; Kaneshima H; Nolan GP; Department of Molecular Pharmacology, Stanford University School; of Medicine, California 94305, USA.


Abstract: Post HIV-1 entry, productive HIV-1 infection of primary T cells requires overcoming several cellular blocks to provirus establishment and replication. Activation of unknown host intracellular events overcomes such inhibitory steps and is concomitant with HIV-1 replication. We show that the transcription factor NFATc was sufficient as a cellular factor to induce a highly permissive state for HIV-1 replication in primary CD4+ T cells. NFATc overcame a blockade at reverse transcription and permitted active HIV-1 replication. Pharmacologic blockade of endogenous NFAT activity by FK506 or CsA inhibited synthesis of reverse transcription and also potently blocked HIV-1 replication. T cells therefore can become competent for HIV-1 replication by control of regulated host factors such as the NFATc transcription factor. The host mechanisms regulated by such permissivity factors are potential targets for anti-HIV-1 therapy.
Keywords: JOURNAL ARTICLE Cell Division Cells, Cultured Cyclosporine/PHARMACOLOGY CD4-Positive T-Lymphocytes/IMMUNOLOGY/VIROLOGY DNA-Binding Proteins/*PHYSIOLOGY Human HIV Infections/*IMMUNOLOGY HIV-1/PHYSIOLOGY/*PATHOGENICITYKWDjournalarticlecelldivisioncells,culturedcyclosporine/pharmacologycd4-positivet-lymphocytes/immunology/virologydna-bindingproteins/KWDphysiologyhumanhivinfections/KWDimmunologyhiv-1/physiology/KWDpathogenicity
990330
A9931088

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .